Showing results (241-250 of 454) with videos related to

Sort By:
Pageof 46
Metabolism: Clinical and Experimental|May 31, 2002
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetesT Temelkova-Kurktschiev, G Siegert, S Bergmann, et al.
Journal of the American Society of Nephrology : JASN|January 1, 1996
Circulating leukocyte integrin expression in Wegener's granulomatosisH Haller, J Eichhorn, K Pieper, et al.
Circulation Research|October 1, 1996
Effects of intracellular angiotensin II in vascular smooth muscle cellsH Haller, C Lindschau, B Erdmann, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|February 1, 1993
Management and complications of urolithiasis during pregnancyH Haller, V Mozetić, D Topljak-Polić, et al.
Journal of Human Hypertension|April 1, 1995
Effect of exogenous mineralocorticoid on platelet cytosolic calcium in normal humansH Haller, A Bock, S Harwig, et al.
Journal of Periodontology|July 29, 2000
Metabolic diseases and their possible link to risk indicators of periodontitisB Noack, I Jachmann, S Roscher, et al.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|December 15, 1988
[Intensive basic therapy decreases the need for drug treatment and improves glucose control: an important result of the diabetes intervention study]M Hanefeld, J Schulze, S Fischer, et al.
Diabetes Care|April 1, 1991
Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDMM Hanefeld, S Fischer, H Schmechel, et al.
Diabetes Research and Clinical Practice|February 19, 2002
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetesM Hanefeld, S M Haffner, M Menschikowski, et al.
Diabetologia|May 13, 2005
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetesB Charbonnel, G Schernthaner, P Brunetti, et al.
Pageof 46